new glp 1 coming to market GLP-1 Drug Market: the rapid growth of the diabetes and obesity drugs How to Invest in GLP-1
Description
The primary endpoint (proportion achieving 5% additional weight loss) was met by 87.5% of the tirzepatide recipients versus 16.5% of the placebo recipients
Retnakaran, R., Kramer, C
Patients taking the 15 mg dose lost an average of roughly 21% of their body weight over 72 weeks
PMID: 34 van RaalteDHvan GenugtenRELinssenMMLOuwensDMDiamantM
[DOI] [PMC free article] [PubMed] [Google Scholar] Pridal L, Ingwersen SH, Larsen FS, Holst JJ, Adelhorst K, Kirk O
